Investors / Investor FAQs
You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.
Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.
This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.
This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.
Information on this website may be revised without any prior notice.
The information contained in this FAQ section of Amarin's website is accurate only as of the date this page was last updated. Amarin disavows any obligation to update the information contained in this FAQ section after such date. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.
Please click here.
Please click here
Please click here
To see the complaint please click here
To see the public interest statement please click here
To see the jurisdiction brief please click here
Amarin is pleased to announce the publication of “Rationale and Design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention Trial” in the March issue of Clinical Cardiology.
The following are key points regarding the study design for REDUCE-IT:
REDUCE-IT: Study Design
- REDUCE-IT is a landmark global study involving approximately 8,000 patients
- It is a randomized, multicenter, double-blind, placebo-controlled study designed to determine if treatment with VASCEPA® 4 g/day versus placebo reduces major adverse cardiovascular events (MACE) in statin-treated patients with persistent hypertriglyceridemia and high cardiovascular risk
- The primary endpoint of the study is the time to the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina
- Secondary endpoints include time to event analyses of components of the primary endpoint
- The study is being conducted under a special protocol assessment agreement with the FDA
For more information, please click here
In September 2014, the National Lipid Association (NLA) launched a nationwide triglyceride campaign during National Cholesterol Education Month. The NLA's announced goal is to encourage patient education and drive discussions about lipid management and the consequences of high cholesterol and triglyceride levels.
According to the NLA, the mission of the campaign is to encourage physicians to inform patients about the importance of proper treatment and prevention as it relates to their entire lipid profile - not just cholesterol, but elevated triglyceride levels, too.
"We want to raise awareness around elevated triglycerides with patients and health care providers alike, as they may unsuspectingly affect patients' health, even if they look and feel healthy," said NLA President Terry A. Jacobson, MD. "Fortunately, health care providers are committed to offering their patients their best care, and we're committed to ensuring they have the tools to do so."
In a recent survey of health care providers, the NLA discovered a need for standard protocols surrounding the measure of patients' total lipid profiles, including triglycerides. To jumpstart these educational and preventive efforts, the NLA urges health care providers to compare patients' triglyceride levels to the following categories:
With this campaign, NLA hopes to provide the necessary resources for clinical practice and education, as well as generate awareness about lipid management.
Amarin is not responsible for the content of NLA's campaign.
Amarin has a co-promotion agreement with Kowa through the end of 2018 under which Kowa uses a portion of the time of their sales force to help educate physicians in the U.S. on the use of Vascepa, along with promotion of its flagship branded statin product, LIVALO® (pitavastatin). This co-promotion arrangement increases both the number of sales targets reached and the frequency of sales calls on existing sales targets. Kowa is responsible for the cost of its sales representatives and related promotional materials. Amarin compensates Kowa with a co-promotion fee based on a percentage of Vascepa gross margins which fee is classified by Amarin as part of selling, general and administrative expenses.
Amarin's ordinary shares, represented by American Depositary Shares, are listed on the NASDAQ Capital Market under the ticker AMRN.
Until July 16th 2008, Amarin's ordinary shares were also listed on London's AIM (ticker: AMRN) and Dublin's IEX (ticker: H2E).
An American Depositary Share (ADS) is a security that represents an ownership interest in the shares of a foreign company trading on a U.S. securities market. The shares represented by the ADSs are held by a U.S. depositary bank and are evidenced by certificates called American Depositary Receipts (ADRs), although the terms ADS and ADR are often used interchangeably. ADRs enable U.S. investors to buy shares in foreign companies without undertaking cross-border transactions (i.e., in U.S. dollars), and they trade, clear and settle in accordance with U.S. market regulations and conventions.
Non-U.S. companies whose securities trade on a U.S. securities market.
One Amarin ADR equals one Amarin ordinary share.
Holders of ADRs may authorize Citibank, Amarin's Depositary, to act as a proxy in exercising voting rights according to the number of ordinary shares represented by their respective ADRs.
Amarin's fiscal year is the 12-month calendar year ending December 31st.
Please visit our website at www.amarincorp.com where you can read more on our executive team, board of directors, company strategy, corporate governance, therapeutic focus, product pipeline and partnering activities.
Amarin is headquartered in Dublin, Ireland.
Amarin's financial statements, including annual reports, can be found on Amarin's website www.amarincorp.com in the Investor Relations section here. Alternatively, you can find all of Amarin's filings with the U.S. Securities and Exchange Commission under the SEC Filings section of the website here.
The U.S. Transfer Agent for Amarin's ADS holders is:
Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
The Registrar for Amarin's ordinary shares is:
Citi - Depositary Receipt Services
388 Greenwich Street
New York, NY 10013
PO Box 4630,
Lancing, West Sussex,
BN99 6QQ, England
Telephone: +44 121 415 7047
The Depositary for Amarin's ADRs is:
Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Ernst & Young LLP
99 Wood Avenue South
Iselin, NJ 08830
You can register to receive updates announced by Amarin by submitting your email address on the Mailing List section of our website, which option can be found on each page of the website www.amarincorp.com. Alternatively you can send an email to firstname.lastname@example.org requesting to be notified of any new updates announced
Please contact: Elisabeth Schwartz
Please submit your question using the form below.
Updated: September 27, 2017 at 12:13 PM Eastern Time